Backed by MaC Venture Capital, Epsilon Ventures, and other strategic investors, the company is redefining how biotech companies run research through intelligent, AI-native systems
CAMBRIDGE, MA · May 27, 2026
Cypher AI, the company building AI-native digital infrastructure for life science research and development (R&D), today announced that it has raised $2 million in seed funding led by MaC Venture Capital, with participation from Epsilon Ventures, Connecticut Innovations, Sparta Group, and LiquidMetal Ventures.
Founded in 2025 by Yaoyu Yang, Cypher AI is creating a new operating layer for biotech research teams by replacing fragmented, manual systems with intelligent infrastructure that unifies experiment design, execution, analysis, and vendor coordination in one platform.
“Life science R&D today still relies heavily on outdated tools such as spreadsheets and fragmented documentation systems that were never designed for modern scientific workflows,” said Yaoyu Yang, PhD, Founder and CEO of Cypher AI. “We are replacing that tech stack with an AI-native platform built for dynamic scientific environments, enabling researchers to design experiments, coordinate execution, manage vendors, and analyze results within a unified intelligent workflow layer.”
Since launching in 2025, Cypher AI has already seen rapid early adoption, working with early-stage and growth-stage biotech companies that are actively modernizing their R&D infrastructure, including DropGenie, Flock Bio, Bioqore and WayBio. To date, more than 800 scientists have run over 100,000 lab and computational workflows on the platform.
“The next generation of biotech won’t scale linearly. It can’t. The biology is too complex and the timelines are too compressed,” said Josh Hinckley, PhD, CEO and co-founder of Bioqore. “What Cypher AI enables is an AI-native software foundation that lets companies like Bioqore grow in a fundamentally different way, where adding a new organism or a new client doesn’t mean rebuilding the stack.”
Cypher AI is building the foundational infrastructure layer for life science R&D, unifying LIMS, ELN, workflow orchestration, and AI-driven analysis into a single system for modern biotech teams. Instead of static tools, it enables adaptive research environments that evolve alongside scientific work.
“Cypher AI is building foundational infrastructure for the next generation of life sciences companies and we’re excited to support them in their mission,” said Adrian Fenty, leading investor at MaC Venture Capital. “Cypher AI is not only improving lab software – it’s rethinking the operating system for life science R&D. That shift has massive implications for speed, accuracy, and scale in biotech.”
Learn more about Cypher AI at https://cypherbio.ai.
We're growing the team with this round. See our open roles →
Cypher AI is building the intelligent digital infrastructure for life sciences R&D. Its AI-native platform unifies experiment design, execution, data management, and analysis into a single system, replacing fragmented tools with a cohesive, adaptive environment for modern research teams. By combining structured data with intelligent workflows, Cypher AI enables scientists to move faster from hypothesis to insight, improve reproducibility, and scale research without added operational complexity. The company works with biotech, pharma, and research organizations to accelerate discovery and innovation across the life sciences.